600 patients66,869 observations120 daysLIVE

Patient P-01494

Synthetic patientNBL-101 · Day 95 · 35–44 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Improving
GI state
Stable
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
68%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 45 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 52 SC-12 recommendedSupportive Compound SC-12
  4. Day 53 Patient declinedNot now
  5. Day 56 GI-04 recommendedGI Support Protocol GI-04
  6. Day 57 Patient acceptedStarted GI-04 in the companion
  7. Day 65 GI symptom burden −23% vs expectedGI Support Protocol GI-04
  8. Day 71 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days
  • Inflammatory activity-13
  • Toxicity-13
  • Nutritional resilience+5
  • Treatment adherence-5
  • GI instability-2

What helped?

  • Supportive Compound SC-12Day 52
    Declined by patient
  • GI Support Protocol GI-04Day 56
    Result: symptom burden −23%
LIFE OS recommendation
Dietary Support Protocol NP-02
53%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 66% showed improvement
  • median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
56.1/100
improving · -2.5 vs previous 14 d
Toxicity
Blood
44.8/100
worsening · +2.8 vs previous 14 d
Sleep quality
Wearable
44.8/100
improving · +2.1 vs previous 14 d
Energy level
Daily log
3.6/10
improving · +0.2 vs previous 14 d
Stress level
Daily log
5.4/10
stable · -0.2 vs previous 14 d
Steps
Wearable
1,865
stable · +44 vs previous 14 d
Adherence
Companion
48.8 %
worsening · -12.8 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 26 from the failing basin, 61 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 77 similar · onset 3 d · confidence 63%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 63%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 63%
Would not help
  • Keep fat low
    GI +3.1 next day on high-intake days · n 27
  • Keep spicy low
    GI +3.1 next day on high-intake days · n 17
  • Keep simple carbs low
    GI +1.9 next day on high-intake days · n 22
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +3.1detractor · 95%
  • Spicy / capsaicin
    +3.1detractor · 95%
  • Simple carbohydrates
    +1.9detractor · 71%
  • Alcohol
    +1no signal · 21%
  • Insoluble fibre
    +0.7no signal · 26%
  • Histamine load
    +0.3no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 70
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 53
  • Drug metabolism and exposure 60
    • DNACYP2D6 poor metabolizer → higher exposure
    • BloodToxicity index 45
  • Butyrate / short-chain fatty acid production 55
    • MicrobiomeButyrate capacity 23/100
    • Daily logFibre intake low in recent food logs
  • Mucosal barrier integrity 50
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 56 and rising
  • Autonomic recovery 20
    • Wearable1,865 steps/day
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
Microbiome
Shannon diversity 2.3 · butyrate capacity 23/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
47 ms
Sleep
6.8 h
Steps
2,085
Resting HR
71 bpm
Daily log: GI score 56, nutritional resilience 43, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0137721%S11AD-05no change42
P-0148321%S14AD-05no change35
P-0168922%S13BR-03no change50
P-0170832%S07CR-01improved59
P-0137129%S06CR-01improved63
P-0169628%S20CR-01improved59
P-0183527%S17CR-01improved56
P-0138826%S17CR-01improved59
P-0144226%S13CR-01improved61
P-0187726%S01CR-01improved67
P-0143022%S05CR-01improved54
P-0134221%S11DT-01improved48